NPSP558

Phase 3Small molecule

Takeda

NPSP558 is one of 19 small molecule programs targeting Hypoparathyroidism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoparathyroidismActive, not recruiting

HypoparathyroidismPhase 3

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Hypoparathyroidism

#DrugCompanyPhaseTrials

Theo-Dur

Pfizer

Approved

3 2

Calciferol

Alnylam Pharmaceuticals

Approved

—3

Rocaltrol

Alnylam Pharmaceuticals

Klor-Con

1 5

One-Alpha

Roche

Phase 2

1 6

Forteo

AAlmaject

Phase 2

2 7

Calcium Citrate

CCampus Bio-Medico University

Approved

1 8

Tums

Otsuka

Phase 2

1 9

Rhpth

Takeda

Phase 3

5 10

Transcon Hgh

VVisen Pharmaceuticals (Shanghai) Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypoparathyroidism4 trials

Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)

Completed· Takeda logo

Takeda·Phase 3·NCT01268098·42 enrolled

A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary

Completed· Takeda logo

Takeda·Phase 3·NCT01455181·24 enrolled

A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)

Completed· Takeda logo

Takeda·Phase 3·NCT01297309·51 enrolled

Show 1 more trial

Use of NPSP558 in the Treatment of Hypoparathyroidism

Completed· Takeda logo

Takeda·Phase 3·NCT00732615·124 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for NPSP558. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NPSP558 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NPSP558. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Takeda

NPSP558

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypoparathyroidism4 trials

References

Drug Info

Quick Facts

Related News